 |
 Video: What is a Stock Split?
|
|
|
| Zomedica is a biopharmaceutical company targeting health and wellness solutions for the companion pet. Co.'s primary drug product candidate is ZM-007, an oral suspension formulation of metronidazole, targeting the treatment of acute diarrhea in small dog breeds and puppies under nine pounds or four kilograms. Co.'s second drug product candidate is ZM-012, a tablet formulation of metronidazole and a complementary formulation to ZM-007, targeting the treatment of acute diarrhea in dogs. Co.'s third drug product candidate is ZM-006, a transdermal gel formulation of methimazole targeting the chronic treatment of hyperthyroidism in cats. According to our Zomedica stock split history records, Zomedica has had 0 splits. | |
|
Zomedica (ZOM) has 0 splits in our Zomedica stock split history database.
Looking at the Zomedica stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Zomedica shares, starting with a $10,000 purchase of ZOM, presented on a split-history-adjusted basis factoring in the complete Zomedica stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
11/22/2017 |
|
| End date: |
05/02/2024 |
|
| Start price/share: |
$2.40 |
|
| End price/share: |
$0.14 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-94.07% |
|
| Average Annual Total Return: |
-35.50% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$592.70 |
|
| Years: |
6.44 |
|
|
|
|
|
